NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Forecast, Price & News

$4.08

+0.03 (+0.74%)

(As of 09/28/2023 ET)

Compare

Today's Range: $3.93
▼
$4.10
50-Day Range: $3.10
▼
$5.35
52-Week Range: $2.81
▼
$13.40

Volume: 14,870 shs
Average Volume: 22,614 shs
Market Capitalization: $15.19 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $55.00

Akari Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,248.0% Upside
$55.00 Price Target
Short Interest: Healthy
0.46% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.91
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

642nd out of 969 stocks

Pharmaceutical Preparations Industry

305th out of 455 stocks

3.5

Analyst's Opinion

Consensus Rating
Akari Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $55.00, Akari Therapeutics has a forecasted upside of 1,248.0% from its current price of $4.08.
Amount of Analyst Coverage
Akari Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.46% of the float of Akari Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Akari Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Akari Therapeutics has recently increased by 116.46%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Akari Therapeutics does not currently pay a dividend.
Dividend Growth
Akari Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AKTX.

2.7

News and Social Media Coverage

News Sentiment
Akari Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Akari Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Akari Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Akari Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
61.80% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Akari Therapeutics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Akari Therapeutics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Akari Therapeutics has a P/B Ratio of 8.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Akari Therapeutics (NASDAQ:AKTX) Stock

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

AKTX Price History

30 days | 90 days | 365 days | Advanced Chart

AKTX Stock News Headlines

September 29, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)

September 28, 2023 | americanbankingnews.com

Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Up 116.5% in September

September 29, 2023 | Stansberry Research (Ad)

1907, 1929, 1998, 2007--and now 2023?

Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.

September 27, 2023 | finance.yahoo.com

Akari Therapeutics to Present at Emerging Growth Conference

September 21, 2023 | finance.yahoo.com

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

September 21, 2023 | americanbankingnews.com

Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com

September 19, 2023 | finance.yahoo.com

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

September 5, 2023 | finance.yahoo.com

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

September 29, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

August 31, 2023 | msn.com

Akari Therapeutics Plc - ADR (AKTX) Price Target Increased by 1900.00% to 56.10

August 21, 2023 | finance.yahoo.com

British pharma opens U.S. headquarters in Boston

August 18, 2023 | finance.yahoo.com

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

August 17, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Announces ADS Ratio Change

August 15, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics, Plc Announces ADS Ratio Change

August 15, 2023 | msn.com

Akari Therapeutics announces ADS ratio change

August 15, 2023 | finance.yahoo.com

Akari Therapeutics, Plc Announces ADS Ratio Change

August 2, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

August 2, 2023 | finance.yahoo.com

Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

July 27, 2023 | finance.yahoo.com

Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

July 19, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer

July 19, 2023 | finance.yahoo.com

Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer

July 15, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

July 13, 2023 | finance.yahoo.com

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

July 11, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy

July 11, 2023 | finance.yahoo.com

Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy

July 6, 2023 | marketwatch.com

Akari Therapeutics Shares Rise 22% After Nomacopan's Positive Orphan Drug Opinion in Europe

July 6, 2023 | finance.yahoo.com

Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation

See More Headlines

Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Company Calendar

Last Earnings: 3/31/2020
Today: 9/29/2023
Next Earnings (Estimated): 9/29/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AKTX
CUSIP: N/A
CIK: 1541157
Web: www.akaritx.com
Phone: 442080040261
Fax: 646-843-9352
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $55.00
High Stock Price Forecast: $80.00
Low Stock Price Forecast: $30.00
Forecasted Upside/Downside: +1,248.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.15
Quick Ratio: 1.15

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.48 per share
Price / Book: 8.50

Miscellaneous

Outstanding Shares: 3,723,000
Free Float: 1,422,000
Market Cap: $15.19 million
Optionable: Not Optionable
Beta: 1.40

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Ms. Rachelle Suzanne Jacques (Age 52)
Pres, CEO & Director
Comp: $1.38M

Ms. Wendy F. DiCicco CPA (Age 56)
CPA, Interim Chief Financial Officer

Ms. Melissa Bradford-Klug (Age 53)
Chief Operating Officer

Dr. Miles Nunn (Age 54)
Chief Scientific Officer

Dr. John F. Neylan III (Age 70)
M.D., Exec. VP & Chief Medical Officer

Ms. Beth-Anne Lang
Sr. VP of Regulatory Affairs

Annie Mack
Financial Controller

Key Competitors

View All Competitors

Institutional Ownership

Cerity Partners LLC
Bought 322,862 shares on 8/14/2023
Ownership: 0.434%

View All Institutional Transactions

AKTX Stock - Frequently Asked Questions

Should I buy or sell Akari Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AKTX shares.
View AKTX analyst ratings or view top-rated stocks.
What is Akari Therapeutics' stock price forecast for 2023?: 2 equities research analysts have issued 1 year target prices for Akari Therapeutics' shares. Their AKTX share price forecasts range from $30.00 to $80.00. On average, they anticipate the company's stock price to reach $55.00 in the next twelve months. This suggests a possible upside of 1,248.0% from the stock's current price.
View analysts price targets for AKTX or view top-rated stocks among Wall Street analysts.
How have AKTX shares performed in 2023?: Akari Therapeutics' stock was trading at $9.3980 at the beginning of the year. Since then, AKTX stock has decreased by 56.6% and is now trading at $4.08.
View the best growth stocks for 2023 here.
Are investors shorting Akari Therapeutics?: Akari Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 17,100 shares, an increase of 116.5% from the August 31st total of 7,900 shares. Based on an average daily volume of 30,800 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.5% of the shares of the company are sold short.
View Akari Therapeutics' Short Interest.
When is Akari Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, September 29th 2023.
View our AKTX earnings forecast.
How were Akari Therapeutics' earnings last quarter?: Akari Therapeutics, Plc (NASDAQ:AKTX) released its quarterly earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) EPS for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00.

When did Akari Therapeutics' stock split?: Akari Therapeutics shares reverse split on the morning of Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Akari Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX).
What is Akari Therapeutics' stock symbol?: Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."
How do I buy shares of Akari Therapeutics?: Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Akari Therapeutics' stock price today?: One share of AKTX stock can currently be purchased for approximately $4.08.
How much money does Akari Therapeutics make?: Akari Therapeutics (NASDAQ:AKTX) has a market capitalization of $15.19 million. The biopharmaceutical company earns $-17,750,000.00 in net income (profit) each year or ($7.00) on an earnings per share basis.
How can I contact Akari Therapeutics?: Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The official website for the company is www.akaritx.com. The biopharmaceutical company can be reached via phone at 442080040261, via email at info@akaritx.com, or via fax at 646-843-9352.

This page (NASDAQ:AKTX) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial